A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

DRUG: Pralsetinib
DRUG: Cabozantinib
DRUG: Vandetanib

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Due to several logistical challenges during start-up which could not be overcome study was withdrawn.

Conditions

Hoffmann-La Roche